ADMA Biologics Inc (ADMA) Earnings Call Analysis
NASDAQ · Healthcare · Biotechnology
Next earnings call: 2026-08-05
(Q2 2026)
— full calendar
Earnings Reports
-
ADMA (ADMA) Q1 2026: Ascentive Grows 28% as Standard IG Downturn Triggers Guidance Reset
May 07, 2026
-
ADMA (ADMA) Q4 2025: Ascentive Drives 51% Growth, Margin Expansion Signals Durable Upside
February 26, 2026
-
ADMA (ADMA) Q3 2025: Yield-Enhanced Batches Lift Gross Margin to 63.7%, Powering 2026 Outlook
November 06, 2025
-
ADMA Biologics (ADMA) Q2 2025: Yield Enhancement Delivers 20% IG Output Gain, Margin Expansion in Focus
August 06, 2025
-
ADMA (ADMA) Q1 2025: Yield Enhancement Approval Unlocks 20% IG Output Surge, Margin Expansion Pathway
July 04, 2025
-
ADMA (ADMA) Q3 2024: Ascentive Drives 78% Revenue Surge, Margin Expansion on Track for 2026
November 07, 2024
-
ADMA (ADMA) Q2 2024: Ascentive Surpasses 50% Revenue Mix, Yield Enhancement Targets 20% Output Gain
August 08, 2024
-
ADMA Biologics (ADMA) Q1 2024: EBITDA Soars 970% as Immunoglobulin Demand Drives Margin Expansion
May 09, 2024